Oncolytics Biotech Inc. announced that it has received a formal letter from The Nasdaq Stock Market LLC, confirming that the company has regained compliance with the minimum bid price requirement. This means Oncolytics is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker 'ONCY'.
The company was previously notified on February 13, 2025, that its common shares failed to maintain a minimum bid price of US$1.00 for 30 consecutive business days. To regain compliance, the closing bid price of Oncolytics' common shares needed to be at or above $1.00 per share for a minimum of 10 consecutive business days.
Oncolytics successfully met this requirement, with its common shares closing at or above $1.00 per share for 10 consecutive business days from July 8, 2025, through July 21, 2025. The resolution of this deficiency removes a significant regulatory overhang and provides stability for the company's listing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.